Validation of Brief Computerized Cognitive Assessment in Multiple Scle
Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) - BICAFMS Study (Brief Cognitive Assessment in French MS Patients)
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Cognitive evaluation
- Expanded Disability Status Scale (EDSS) score
What it measured
Main measures
Prediction by the z score BCCAMS of cognitive impairment (at least two tests MACFIMS battery <1.5 SD of control subjects
At the inclusion (Day 0)
Thinking and memory
Other measures (6)
Determine values of neuropsychological tests in healthy according to age subjects, gender and the level education
At the inclusion (Day 0) and at 1 and 6 months after the inclusion (Day 0)
Ability of the CEVMT to detect episodic memory deficiencies in patients with multiple sclerosis, as compared to established tests of episodic memory
At the inclusion (Day 0) and at 1 and 6 months after the inclusion (Day 0)
Thinking and memoryCorrelation between alternate forms of the CEVMT and the Brief visual memory test-revised (BVMT-R)
At the inclusion (Day 0) and at 1 and 6 months after the inclusion (Day 0)
Thinking and memoryPrediction between cognitive impairment and occupational status/leisure activities
At the inclusion (Day 0) and 6 months after the inclusion (Day 0)
Thinking and memoryEffect of possible confounders on results of cognitive testing, including depression, mood, anxiety and fatigue
At the inclusion (Day 0) and at 1 and 6 months after the inclusion (Day 0)
Thinking and memoryFatigueMood and sleepReproducibility of CSCT, CEVMT and the symbol-digit modalities test in clinical settings in patients with multiple sclerosis
At 1 and 6 months after the inclusion (Day 0)
Who could take part
Relapsing and progressive · 18 to 64
Show the full criteria
Inclusion criteria
Patients : * Aged 18-64 years * Francophone * MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms * Having signed an informed consent (later than the day of inclusion and before any examination required by research) * Being affiliated to health insurance Controls: * Aged 18-64 years * Francophone * Having signed an informed consent (later than the day of inclusion and before any examination required by research) * Being affiliated to health insurance
Exclusion criteria
Patients: * Other neurological diseases with impact on cognitive functions. * Severe psychiatric disease or severe depression. * Current Dependence on alcohol or drugs. * Modification or stop of psychotropic treatment in less than a month. * Modification of MS treatment in less than a month. * Visual, visual-motor and / or motor impairments excluding the ability to perform cognitive tests. * Pregnant Controls: * Neurologic disease and known chronic systemic with impact on cognitive functions. * Severe psychiatric disease or severe depression. * Current Dependence on alcohol or drugs. * Psychotropic treatment * Cognitive complaint * Prior cognitive testing with the same tests less than one year. * Pregnant
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Cognitive disorders are common in early stage of Multiple Sclerosis (MS) and concern mainly information processing speed (IPS) which also influences with other cognitive functions such as attention, working memory and executive functions. The investigators validated a computerized test of IPS, the computerized speed cognitive test (CSCT), which can detect disorders of IPS in MS. A short battery was proposed, the brief cognitive assessment for multiple sclerosis (BICAMS) battery, which combines the Symbol-Digit Modalities-test (SDMT), a test of the IPS, and two measures of episodic memory. On the same principle, the investigators propose to validate a short computerized battery to improve the feasibility (brief computerized cognitive assessment (BCCAMS)) combining the CSCT and a computerized test of visual episodic memory. Purpose: to establish the screening value of a brief computerized cognitive assessment (BCCAMS) combining the computerized speed cognitive test (CSCT) and a new computerized episodic visual memory test (CEVMT) in French-speaking patients with multiple sclerosis as compared to a reference battery (MACFIMS).
Papers
Results
Ruet A, Brochet B. Cognitive assessment in patients with multiple sclerosis: From neuropsychological batteries to ecological tools. Ann Phys Rehabil Med. 2020 Mar;63(2):154-158. doi: 10.1016/j.rehab.2018.01.006. Epub 2018 Feb 17.Results
Maubeuge N, Deloire MSA, Brochet B, Erhle N, Charre-Morin J, Saubusse A, Ruet A; BICAFMS study investigators. French validation of the Brief International Cognitive Assessment for Multiple Sclerosis. Rev Neurol (Paris). 2021 Jan-Feb;177(1-2):73-79. doi: 10.1016/j.neurol.2020.04.028. Epub 2020 Jul 23.Results
Maubeuge N, Deloire MSA, Brochet B, Ehrle N, Charre-Morin J, Saubusse A, Ruet A; BICAFMS study investigators. Validation of the French version of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Mult Scler Relat Disord. 2021 Feb;48:102692. doi: 10.1016/j.msard.2020.102692. Epub 2020 Dec 17.Results
Maubeuge N, Deloire MS, Brochet B, Charre-Morin J, Saubusse A, Ruet A. Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries. Mult Scler. 2022 Jun;28(7):1112-1120. doi: 10.1177/13524585211054006. Epub 2021 Nov 12.
Loading reviews and guidelines…
History
Started
Feb 2015
Main results due
Feb 2018
Finished
Feb 2018